Qtron Investments’s Viking Therapeutics VKTX Stock Holding History

Qtron Investments’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-22,791	Closed	-$68K	–	438
2022 Q1	$68K	Buy	+22,791	New	+$81.8K	0.02%	332

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Qtron Investments's VKTX Position: Q2 2022 in Review

Qtron Investments sold out of Viking Therapeutics (VKTX) in Q2 2022, closing a stake of 22,791 shares — an estimated $68K sold.

Qtron Investments first reported a position in VKTX in Q1 2022 and held it in 1 quarter. The position peaked at $68K in Q1 2022. 114 funds tracked by Wall St. Rank hold VKTX as of Q2 2022.

Qtron Investments reported no remaining Viking Therapeutics position as of Q2 2022 after selling out during the quarter.
Qtron Investments sold 22,791 Viking Therapeutics shares in Q2 2022, an estimated $68K.
Qtron Investments first reported a position in Viking Therapeutics in Q1 2022 and held it in 1 quarter.
Qtron Investments's Viking Therapeutics position peaked at $68K in Q1 2022.
114 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2022.

Based on Qtron Investments's 13F filing for Q2 2022, filed 10 Aug 2022.